/
FULC
$3.73-$0.07 (-1.84%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$253.2M
67M shares
52-week range
$2.83 – $15.74
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | $0 |
| Cost of revenue | $1.3M | $2.1M | $59.0M | $69.7M | $76.8M | $71.8M | $63.4M | $1.4M |
| Gross profit | −$1.3M | −$2.1M | −$50.2M | −$50.5M | −$70.4M | −$69.0M | $16.6M | −$1.4M |
| Gross margin | — | — | -569.2% | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| R&D | $25.2M | $43.4M | $59.0M | $69.7M | $76.8M | $71.8M | $63.4M | $56.1M |
| Operating income | −$33.5M | −$58.6M | −$71.6M | −$81.1M | −$112.6M | −$110.7M | −$21.9M | −$84.8M |
| EBITDA | −$32.2M | −$80.6M | −$69.2M | −$78.3M | −$109.7M | −$95.2M | −$18.2M | −$73.5M |
| Net income | −$32.6M | −$82.7M | −$70.8M | −$80.8M | −$109.9M | −$97.3M | −$9.7M | −$74.9M |
| Net margin | — | — | -802.7% | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (diluted) | -1.92 | -3.49 | -2.70 | -2.22 | -2.35 | -1.59 | -0.16 | -1.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $311890 | $-0.81 | $-1.26–$-0.42 | 7 |
| 2027 | $361M | $-0.71 | $-1.81–$-0.02 | 7 |
| 2028 | $54M | $-0.65 | $-1.65–$-0.01 | 5 |
| 2029 | $117M | $-0.32 | $-0.32–$-0.32 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.01
Price
$3.73
Implied downside
-19%
Peer comparison
Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
www.fulcrumtx.com- Employees
- 55
- IPO / List date
- Jul 18, 2019
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds FULC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 13,600 | $104.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FULC yet.
